Research Article

Identification of Novel Hypoxia Subtypes for Prognosis Based on Machine Learning Algorithms

Jiawei Wang,¹ Tuo Li,² Songquan Wei,³ Gengye Zhao,³ Cong Ye,⁴ Qiuping Ma,⁴ Jinchun Ma,④ and Xiaoyan Cheng①

¹Department of Obstetrics and Gynecology, Nantong Maternity and Child Health Care Hospital Affiliated to Nantong University, Nantong 226018, Jiangsu Province, China
²Department of Endocrinology, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China
³The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China
⁴Department of Obstetrics and Gynecology, Soochow University Affiliated Taicang Hospital (The First People’s Hospital of Taicang), Suzhou, Jiangsu 215400, China

Correspondence should be addressed to Jinchun Ma; 1452212929@qq.com and Xiaoyan Cheng; 1012770174@qq.com

Received 6 July 2022; Revised 21 July 2022; Accepted 25 July 2022; Published 12 September 2022

Academic Editor: Mingjun Zheng

Copyright © 2022 Jiawei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. A reduced level or tension or the deprivation of oxygen is termed hypoxia. It is common for tumours to outgrow their natural source of nutrients, which causes hypoxia in some tumour regions. Hypoxia affects ovarian cancer (OC) in several ways.

Methods. In this study, the expression patterns of prognostic hypoxia-related genes were curated, and consensus clustering analyses were performed to determine hypoxia subtypes in OC included in The Cancer Genome Atlas cohort. Two hypoxia-related subtypes were observed and considered for further investigation. The analyses of differentially expressed genes (DEGs), gene ontology, mutation, and immune cell infiltration were performed to explore the underlying molecular mechanisms.

Results. In total, 377 patients with OC were classified into two subgroups based on the subtype of hypoxia. The clinical outcome was considerably poor for patients with hypoxia subtype 2. DEG and protein-protein interaction analyses revealed that the expression levels of CLIP2 and SH3PXD2A were low in OC tissues. Immune cell infiltration analysis revealed that the subtypes were associated with the tumour microenvironment (TME).

Conclusion. Our findings established the existence of two distinctive, complex, and varied hypoxia subtypes in OC. Findings from the quantitative analysis of hypoxia subtypes in patients improved our understanding of the characteristics of the TME and may facilitate the development of more efficient treatment regimens.

1. Introduction

Ovarian cancer (OC) is by far the deadliest type of gynecological cancer and the fifth leading cause of cancer-associated death among females [1]. Early diagnosis of OC is challenging owing to the absence of disease-specific symptoms. Subsequently, a majority of women are diagnosed with OC at an advanced stage [2]. Long-term exposure to steroid hormones contributes to several risk factors. Even though hormone synthesis slows down after menopause, women who have been exposed to these hormones continuously and chronically throughout their lives are more likely to develop OC [3, 4]. Currently, the standard-line therapy for OC comprises cytoreductive surgery and chemotherapy (usually paclitaxel and carboplatin) to remove excess tissue [5]. However, even though chemotherapy is occasionally effective in treating early-stage cancer, many patients ultimately develop chemoresistance and experience recurrence [6]. Chemoresistance is driven by molecular and genetic changes that are unknown, and this lack of mechanistic insight hinders its prevention and prediction. [7, 8] Owing to this, novel therapeutic techniques are needed to avoid chemoresistance and increase the success rate of therapy.
Hypoxia is reportedly associated with chemoresistance via several pathways. Altering the metabolism of cancer cells is one of the ways through which hypoxia may cause chemoresistance in patients with cancer. OC cells, when exposed to hypoxia, are subjected to metabolic reprogramming, which alters the glycolytic pathway and enhances resistance to carboplatin [9]. Hypoxia in OC is associated with altered levels of circulating microRNAs (miRNAs), and these miRNA expression patterns are linked to a greater risk of OC development. However, research on the mechanisms underlying hypoxia in OC is insufficient.

Immunotherapy is considered a potentially viable treatment option since it has high degrees of specificity, long-term benefits, and minimal adverse effects. Owing to extensive variability, including clinical and pathological parameters, molecular characteristics, and the immune cell milieu, among other factors, the response rate to immune checkpoint blockade treatment in patients with OC remains as low as 15% [10–12]. Given the heterogeneity of OC, the accurate identification of the specific advantages of immunotherapy in patients is essential for its further advancement [13]. In this study, two distinct hypoxia subtypes were investigated, each characterised by distinct immune infiltrates and immune responses. Additionally, an immune scoring system was developed for patients with OC, which yielded a thorough understanding of the characteristics of the tumour microenvironment (TME) and prompted the development of efficacious treatment modalities.

2. Material and Methods

2.1. Data Resources. The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) project was used to collect and process the molecular data of 377 individuals who had been diagnosed with OC. The GDC data portal (https://portal.gdc.cancer.gov) was used to obtain the transcriptomic profiles (HTSeq-fragments per kilobase of exon per million mapped fragments (FPKM)) and clinical data for TCGA-OC dataset. The Ensembl IDs were translated to gene symbols, and the FPKM values were transformed into transcripts per million [14].

2.2. Identification of Hypoxia Subtypes Using Consensus Clustering. Using the ConsensusClusterPlus tool, subtypes of hypoxia were determined. Hypoxia-related genes are listed in Table 1. To properly classify OC samples, a consensus matrix was developed using consensus clustering. Consistent with the partitioning around the medoids algorithm and using the Pearson correlation coefficient as the distance measure, 500 bootstraps were provided, with each comprising patients with OC included in TCGA cohort. The number of clusters was determined to be two–eight. Additionally, a consensus clustering approach was adopted to classify the genes immunologically related to the prognosis. The consistency matrix and the consistency cumulative distribution function were selected as the methods for optimal classification [15].

2.3. Identification of Differently Expressed Genes (DEGs). The significance analysis built into the empirical Bayes techniques used as a part of the limma package was used to detect DEGs. The cut-off values for selecting the relevant DEGs were a P-value <0.01 and a |logFC| >1. Additionally, using the cbioPortal web platform (https://www.cbioportal.org), we created a network of DEGs and their coexpression genes [16,17].

2.4. Gene Ontology (GO) and Pathway Enrichment Analysis. The data were evaluated using functional enrichment analysis to confirm the fundamental function of putative targets. GO is a technique extensively used to annotate genes with functions, including cellular components (CC), biological pathways (BP), and molecular function (MF). ClusterProfiler version 3.18.0 in R was used to examine the GO function of putative targets and enrich the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to gain

| Table 1: Hypoxia-related genes. |
|-------------------------------|
| Gene symbol | Gene symbol |
| PSMB6      | PSMA1       |
| PSMB5      | PSMA8       |
| HIGD1A     | PSMC6       |
| EGLN2      | PSMD9       |
| PSMD1      | RBX1        |
| PSMA7      | PSMC5       |
| HIF1AN     | PSMB1       |
| PSMC2      | PSMB8       |
| PSMD3      | PSMA4       |
| EP300      | VHL         |
| VEGFA      | HIF3A       |
| ELOC       | WTIP        |
| PSMC3      | EGLN3       |
| PSME4      | ARNT        |
| UBE2D2     | PSMD12      |
| UBC        | PSMA6       |
| PSM11      | EGLN1       |
| PSM10      | PSMB3       |
| PSM10      | PSMD8       |
| PSM13      | CUL2        |
| ELOB       | PSMA3       |
| PSME2      | PSMC1       |
| CREBBP     | SEM1        |
| UBB        | EPSA1       |
| PSM6       | PSMA5       |
| PSM13      | PSMA2       |
| PSM11      | EPO         |
| CA9        | PSME3       |
| PSM11      | PSMD7       |
| AJUBA      | PSMB9       |
| UBE2D1     | PSME1       |
| PSMD14     | HIF1A       |
| PSMC4      | CITED2      |
| PSMB2      | UBA52       |
| PSMB4      | UBE2D3      |
| LIMD1      | PSMD4       |
| PSMD2      | RPS27A      |
| PSMB7      |             |
2.5. Mutation Analysis. Using TCGA dataset (https://portal.gdc.com), we retrieved the RNA-seq expression patterns, genetic mutation, and relevant clinical data of 376 patients. The metaTools package of R software was used to retrieve data on mutations, which were further visualised by the program. Genes with a higher mutational frequency detected in 376 patients in the histogram are demonstrated.

2.6. Protein-Protein Interaction (PPI) Enrichment Analysis. An enrichment study of PPI was performed using the Metascape database for each gene list that was provided. Only the physical interactions observed in the STRING (with a score greater than 0.132) and BioGRID were considered. The resultant network included the subset of proteins that physically interacted with at least one other member in the list. The molecular complex detection (MCODE) algorithm 10 is used to determine the network components that are densely connected when the number of proteins in the network ranges between 3 and 500 [19].

2.7. Gene Expression Validation and Survival Analysis of Hub Genes. To further confirm the significant role of hub genes in the pathogenesis and prognosis of OC, we used the Gene Expression Profiling Interactive Analysis (GEPIA) database to retrieve information on the expression of these genes and their prognostic significance. The GEPIA database, an interactive online platform for analysing gene expression, contains data on 8,587 normal samples and 9,736 tumour samples [20].

2.8. Cox Analysis. To define the appropriate terms to generate the nomogram, both univariate and multivariate Cox regression analyses were used. Using the “forestplot” R package, we generated a forest plot to display the P-value, HR, and 95% confidence interval (CI) for each variable. We created a nomogram based on the findings of a multivariate Cox proportional hazard analysis to accurately predict the 1-year overall recurrence.

2.9. Immune Cell Infarction Analysis. We used immuneconv, an R software package that incorporates the two most recent algorithms, ssGSEA and CIBERSORT, to validate the outcomes of the immune score assessment. These algorithms are benchmarked and have distinct advantages. SIGLEC15, TIGIT, PDCD1LG2, HAVCR2, PDCD1, LAG3, CTLA4, and CD274 were determined to produce transcripts that are important for immune checkpoints, and the expression levels of these eight genes were measured. R foundation for statistical computing (version 4.0.3) was used for implementing the aforementioned analytical techniques. In addition, we used the ggplot2 and pheatmap functions of the R package [21].

2.10. Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR). Total RNA was extracted from para-neoplastic and tumour tissues of patients with OC using the TRIzol reagent (Sigma-Aldrich, St. Louis, MO, USA). Furthermore, RNA from each sample (2 μg) was subjected to qRT-PCR using the FastStart Universal SYBR® Green Master (Roche, Germany) on an ABI QuantStudio5 Q5 real-time PCR system (Thermo Fisher Scientific, USA). Afterward, we used cDNA as a template in 20 μL reaction volume (containing 10 μL of a PCR mixture, 0.5 μL of reverse and forward primers, 2 μL of cDNA template, and an appropriate volume of water). We conducted PCR as follows: cycling began with an initial DNA denaturation step at 95°C for 30 s, followed by 45 cycles at 94°C for 15 s, 56°C for 30 s, and 72°C for 20 s. Each sample was assessed in triplicates. Using the 2^−ΔΔCt method, readings from the threshold cycle (CT) were obtained and further standardised to the levels of glyceraldehyde 3-phosphate dehydrogenase in each sample. The mRNA expression levels were compared to those in para-cancerous tissue controls. The primer pair sequences corresponding to the target genes are presented in Table 2.

3. Results

3.1. Characterisation of Two Distinct Subtypes of OC Hypoxia. The mRNA expression profiles of hypoxia-associated genes in OC tissues were obtained from the TCGA cohort and used in this investigation. Patients with OC were clustered using consensus clustering methods in line with the expression profiles of prognostic hypoxia-related genes. The stability of clustering was analysed with k-values ranging from 2 to 8. As a direct consequence of this, selecting k = 2 was the best alternative. Two distinct immune subtypes, immune subtype 1 (n = 134) and immune subtype 2 (n = 242), were identified in patients with OC. Survival analysis revealed that patients with subtype 2 had a poorer outcome (Figure 1(b)).

3.2. Determination of DEGs in Subtypes. The limma program was used to conduct the analysis. The results demonstrated that 375 DEGs, including one gene that was considerably upregulated and 374 genes that were downregulated. The volcano plot of gene expression profile data in each dataset is presented in Figure 1(c). The heatmap of the top DEGs is presented in Figure 1(d).

3.3. GO Enrichment Analysis and KEGG Pathways of DEGs. The potential mRNA targets were analysed using the GO database. The findings obtained from the MF, CC, and BP of putative targets clustered, based on the clusterProfiler program in R software, revealed a substantial enrichment of DEGs in functions such as the modulation of synapse structure or activities, modulation of synapse organization, modulation of small GTPase and mediated signal
Table 2: Primers of CLIP2, SH3PXD2A and GAPDH.

| Gene   | Forward primer sequence (5'-3') | Reverse primer sequence (5'-3') |
|--------|---------------------------------|---------------------------------|
| CLIP2  | TTAGCGGACAACAGGCTGAC            | GCTGGAGCTCCTCGATTTCA            |
| SH3PXD2A| GACTGTACTGCTTAGGGGTGC           | CGGCTCTCGTTCTTCTCGAT           |
| GAPDH  | AATGGGCAGCCGTTAGGAAA            | GCCCAATACGACCAAATCAGAG          |

Figure 1: Continued.
Figure 1: (a) A heatmap illustrating the sample clustering when consensus $k = 2$, based on the expression profile of prognostic immune-related genes. (b) Analysis of survival using the Kaplan-Meier method for the clusters. (c) The fold change values and the P-adjust parameters were used to construct the volcano plot. Upregulated genes are represented by red dots; downregulated genes are represented by blue dots; non-significant genes are represented by grey dots. (d) The heatmap of differential gene expression. (e) The KEGG signalling pathways with significant enrichment illustrate the main biological activities of significant candidate mRNAs. The gene ratio is indicated by the abscissa, and the enriched pathways are indicated by the ordinate. Analysis of putative mRNA targets using the gene ontology (GO) database.
transduction modulation of the extracellular matrix organisation (Figure 1(e)).

3.4. Mutation State in Subtypes. We examined how single-nucleotide polymorphisms were distributed among the OC samples. Overall, genetic mutations in immune subtypes 1 and 2 were observed in 102 and 161 OC samples, respectively (Figures 2(a) and 2(b)). Lollipop charts of the mutated TP53 gene, the figure caption displays the somatic mutation rate, and the subheadings depict the name of somatic mutation (Figure 2(c)).

3.5. Establishment of the PPI Network and Module Analysis. The Metascape database served as the foundation for the establishment of a PPI network of DEGs (Figure 3(a)). The two most significant modules, one comprising upregulated genes and the other comprising downregulated genes, were extracted from this PPI network using MCODE. Hub genes were selected for further analysis. Many hub genes were observed to be enriched in certain pathways, including the PI3K-Akt signalling pathway (Figure 4(a)).

3.6. Analysis and Validation of Hub Genes. The screening of the GEPIA database revealed that CLIP2 and SH3PXD2A displayed substantial differences in expression between tumour and normal specimens in OC (Figures 4(b) and 4(c)). The findings of GEPIA for overall survival (OS) revealed that patients with OC were categorised into high- and low-expression groups. We confirmed that the overexpression of CLIP2 and SH3PXD2A was associated with a significantly poor OS in patients.

3.7. Survival Analysis. The one-year survival rate for patients with OC may be predicted using the nomogram. We established a calibration curve for the OS based on the nomogram model in the discovery subgroup. The univariate
and multivariate analyses showed that CLIP2 and SH3PXD2A expressions functioned independently as a risk factor for OC (Figures 4(d) and 4(e)).

3.8. Two Hypoxia Subtypes with Different Immune Infiltrates and Immune Responses. Using the CIBERSORT algorithm, the landscape of tumour-infiltrating lymphocytes was obtained, and 21 types of immune cell profiles of patients with glioma were determined from TCGA. The proportion of cells such as naïve B cells and CD8+ T cells differed significantly between the hypoxia subtypes (Figure 5(a)). Checkpoint analysis revealed that hypoxia subtype 2 has a higher expression in CD274, HAVCR2, ODCD1LG2, and SIGLEC15(Figure 5(b)). Finally, ssGSEA revealed that CLIP2 and SH3PXD2A expression was positively correlated with immune cells, such as Tem and natural killer (NK) cells (Figures 5(c) and 5(d)).

3.9. Evaluation of Gene Expression in OC. To validate the expression of the CLIP2 and SH3PXD2A genes in the tumour and nontumour adjacent tissues, the relative mRNA expression levels of CLIP2 and SH3PXD2A in both tumour
Figure 4: Continued.
Figure 4: (a) Pop plot of pathway enrichment of hub genes. (b–e) The level of expression of hub genes and the significance of their predictive value based on data from the Gene Expression Profiling Interactive Analysis (GEPIA) database. (f) Nomograms can predict the 1-year overall survival of patients with OV cancer. (g-h) The P-value, risk coefficient (HR) and confidence interval analysed by multivariate and univariate Cox regression.

Figure 5: Continued.
and nontumour tissues were determined using qPCR. The average expression level of **CLIP2** and **SH3PX2A** in OC tissue was considerably less than that in normal tissues (Figure 6).

### 4. Discussion

OC is a severe epithelial cancer that predominantly contributes to cancer-associated death among females [22–24]. The treatment options available for OC are clinically ineffective and have a detrimental effect on patients’ quality of life. Thus, viable and effective therapies are urgently needed. [25, 26] A growing body of evidence has illustrated that the hypoxia microenvironment plays a critical role in immune response and carcinogenesis based on the dysregulated expression of genes associated with hypoxia. [27, 28] Most research conducted in the past on hypoxia in OV has focused on a single regulator. Hypoxia-inducible factor-1α, for instance, has been reported to play an integral role in various processes, including the

![Figure 5: (a) The boxplot of immune infarction cells in hypoxia types 1 and 2. (b) The expression and distribution of immune checkpoint genes in tissues affected by hypoxia types 1 and 2. (c) Barplot of immune cell infarction in high and low **CLIP2** expression obtained via single-sample Gene Set Enrichment Analysis (ssGSEA). (d) Barplot of immune cell infarction of high and low **SH3PX2A** expression via ssGSEA.]
promotion of OC immunosuppression, tumour metastasis, and chemoresistance.

In this study, two subtypes of hypoxia were identified using consensus clustering analysis, each of which was based on the prognostic immune-relevant genes. Particularly, hypoxia subtype 2 displayed a more unfavourable clinical outcome than hypoxia subtype 1. Cancer is a malignant neoplasm that may be caused by genetic mutations and variations [29]. Hypoxia subtype 1 was characterised by the presence of more prevalent genetic alterations. Alterations in the expression of several genes, including TP53, have been observed to be correlated with the success of immunotherapies and exhibit a predictive potential [30]. In the OC samples, the TP53 gene was the first to undergo mutation. In hypoxia subtype 1, the TP53 gene was reported to have a greater incidence of mutations than that in hypoxia subtype 2. Our results suggest a difference among the hypoxia subtypes in terms of genetic changes and mutations.

In this study, we identified 374 genes generated from the hypoxia subtypes, which had the potential to influence pathways such as the PI3K-Akt signalling pathway. Hub genes, such as CLIP2 and SH3PXD2A, were selected and used for further investigation. Recently, the expression of SH3PXD2A-AS1 was observed to be related to OC; however, the underlying molecular mechanism remains unknown. Simultaneously, the absence of SH3PXD2A has been reported in the OV area. Nonetheless, further investigation is warranted. The results of ssGSEA demonstrated that the decrease in CLIP2 and SH3PXD2A expression may influence the infiltration levels of immune cells, such as NK cells. Finally, PCR results confirmed these patterns in OC tissues. While this work is a bioinformatics and pcr analysis, more investigation should be performed in clinic for future application.

A well-defined hypoxia score has significant benefits over standard prognostic markers used for OC. Therefore, the hypoxia score may be used to compare various hypoxia-modulating components and aid the exploration of how tumour cells interact with the immunological milieu. In addition, it helps stratify patients with OC into various groups based on their potential response to chemotherapy or other immune checkpoint blockades. Thus, CLIP2 and SH3PXD2A should be further investigated and could be novel biomarkers for patients with OC.

**Abbreviations**

OC: Ovarian cancer
TCGA: The Cancer Genome Atlas
DEGs: Differentially expressed genes
TME: The tumour microenvironment
miRNAs: microRNAs
FPKM: Fragments per kilobase of exon per million mapped fragments
TPM: Transcripts per million
GO: Gene Ontology
CC: Cellular components
BP: Biological pathways
MF: Molecular function
KEGG: Kyoto Encyclopedia of Genes and Genomes
PPI: Protein-Protein Interaction
MCODE: Molecular Complex Detection
GEPIA: Gene Expression Profiling Interactive Analysis
CI: Confidence interval
qRT-PCR: Quantitative Reverse-Transcription Polymerase Chain Reaction
NK cells: Natural killer cells

**Data Availability**

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Jiawei Wang and Tuo Li contributed equally to this work.
Acknowledgments

This work was funded by the Nantong Science and Technology Program (MS12021099), the Hong Kong Scholars Program (XJ2016016), and the Shanghai Pujiang Program (2020PJ063).

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] D. Badgwell and R. C. Bast Jr, "Early detection of ovarian cancer," Disease Markers, vol. 23, no. 5-6, pp. 397–410, 2007.

[3] A. L. Shafirir, A. Babic, M. Gates Kuliszewski et al., "Estrogen receptor-β expression of ovarian tumors and its association with ovarian cancer risk factors," Cancer Epidemiology, Biomarkers & Prevention, vol. 29, no. 11, pp. 2211–2219, 2020.

[4] W. Wang, Q. Wu, Z. Wang et al., "Development of a prognostic model for ovarian cancer patients based on novel immune microenvironment related genes," Frontiers in Oncology, vol. 11, Article ID 647273, 2021.

[5] B. Orr and R. P. Edwards, "Diagnosis and treatment of ovarian cancer," Hematology-Oncology Clinics of North America, vol. 32, no. 6, pp. 943–964, 2018.

[6] INVALID CITATION !!! 6. https://community.endnote.com/t/invalid-citation/259536.

[7] S. B. Hooks, P. Callihan, M. K. Altman, J. H. Hurst, M. W. Ali, and M. M. Murph, "Regulators of G-protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells," Molecular Cancer, vol. 9, no. 1, p. 289, 2010.

[8] R. C. Bast, B. Hennessy, and G. B. Mills, "The biology of ovarian cancer: new opportunities for translation," Nature Reviews Cancer, vol. 9, no. 6, pp. 415–428, 2009.

[9] M. Alharbi, A. Lai, S. Sharma et al., "Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence," Cancers, vol. 13, no. 14, p. 3388, 2021.

[10] Y. Gao, L. Chen, G. Cai et al., "Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study," OncolImmunology, vol. 9, no. 1, Article ID 1760067, 2020.

[11] R. S. Riley, C. H. June, R. Langer, and M. J. Mitchell, "Delivery technologies for cancer immunotherapy," Nature Reviews Drug Discovery, vol. 18, no. 3, pp. 175–196, 2019.

[12] R. Derynck, S. J. Turley, and R. J. Akhurst, "TGFβ biology in cancer progression and immunotherapy," Nature Reviews Clinical Oncology, vol. 18, no. 1, pp. 9–34, 2021.

[13] D. Hao, J. Liu, M. Chen et al., "Immunogenic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity," Clinical Cancer Research, vol. 24, no. 15, pp. 3560–3571, 2018.

[14] W. Hu, G. Wang, Y. Chen, L. B. Yarmus, B. Liu, and Y. Wan, "Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma," Aging, vol. 12, no. 16, pp. 16514–16538, 2020.

[15] W. Qi and Q. Zhang, "Identification and validation of immune molecular subtypes and immune landscape based on colon cancer cohort," Frontiers of Medicine, vol. 9, Article ID 827695, 2022.

[16] Q. Wu, B. Zhang, Z. Wang et al., "Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer," Pathology, Research & Practice, vol. 215, no. 5, pp. 1038–1048, 2019.

[17] M. E. Ritchie, B. Phipson, D. Wu et al., "Limma powers differential expression analyses for RNA-sequencing and microarray studies," Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015.

[18] L. Zhu, X. Liu, W. Zhang, H. Hu, Q. Wang, and K. Xu, "MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder," BMC Cancer, vol. 22, no. 1, p. 556, 2022.

[19] Y. Zhou, B. Zhou, L. Pache et al., "Metascape provides a biologist-oriented resource for the analysis of systems-level datasets," Nature Communications, vol. 10, no. 1, p. 1523, 2019.

[20] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," Nucleic Acids Research, vol. 45, no. 1, pp. W98–W102, 2017.

[21] A. M. Newman, C. L. Liu, M. R. Green et al., "Robust enumeration of cell subsets from tissue expression profiles," Nature Methods, vol. 12, no. 5, pp. 453–457, 2015.

[22] D. Matei and K. P. Nephew, "Epigenetic attire in ovarian cancer: the emperor’s new clothes," Cancer Research, vol. 80, no. 18, pp. 3775–3785, 2020.

[23] The Lancet Oncology, "Ovarian cancer: breaking the silence," The Lancet Oncology, vol. 13, no. 2, p. 111, 2012.

[24] P. B. Ottevanger, "Ovarian cancer stem cells more questions than answers," Seminars in Cancer Biology, vol. 44, pp. 67–71, 2017.

[25] J. Liu and U. A. Matulonis, "New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances," Clinical Cancer Research, vol. 20, no. 20, pp. 5150–5156, 2014.

[26] F. Ricci, M. Broglini, and G. Damia, "Revisiting ovarian cancer preclinical models: implications for a better management of the disease," Cancer Treatment Reviews, vol. 39, no. 6, pp. 561–568, 2013.

[27] K. DePeaux and G. M. Delgoffe, "Metabolic barriers to cancer immunotherapy," Nature Reviews Immunology, vol. 21, no. 12, pp. 785–797, 2021.

[28] X. Jing, F. Yang, C. Shao et al., "Role of hypoxia in cancer therapy by regulating the tumor microenvironment," Molecular Cancer, vol. 18, no. 1, p. 157, 2019.

[29] K. L. Kanchi, K. J. Johnson, C. Lu et al., "Integrated analysis of germline and somatic variants in ovarian cancer," Nature Communications, vol. 5, no. 1, p. 3156, 2014.

[30] H. Sun, S. Y. Liu, J. Y. Zhou et al., "Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma," EBioMedicine, vol. 60, Article ID 102990, 2020.

[31] N. Li and X. Zhan, "Identification of clinical trait-related IncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer," The EPMA Journal, vol. 10, no. 3, pp. 273–290, 2019.